AU2021280214A1 - Treatment of cancer - Google Patents

Treatment of cancer Download PDF

Info

Publication number
AU2021280214A1
AU2021280214A1 AU2021280214A AU2021280214A AU2021280214A1 AU 2021280214 A1 AU2021280214 A1 AU 2021280214A1 AU 2021280214 A AU2021280214 A AU 2021280214A AU 2021280214 A AU2021280214 A AU 2021280214A AU 2021280214 A1 AU2021280214 A1 AU 2021280214A1
Authority
AU
Australia
Prior art keywords
lag
protein
derivative
subject
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021280214A
Other languages
English (en)
Inventor
Frédéric Triebel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immutep SAS
Original Assignee
Immutep SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2008037.0A external-priority patent/GB202008037D0/en
Priority claimed from GBGB2018062.6A external-priority patent/GB202018062D0/en
Application filed by Immutep SAS filed Critical Immutep SAS
Publication of AU2021280214A1 publication Critical patent/AU2021280214A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AU2021280214A 2020-05-28 2021-03-24 Treatment of cancer Pending AU2021280214A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB2008037.0A GB202008037D0 (en) 2020-05-28 2020-05-28 Treatment of cancer
GB2008037.0 2020-05-28
RU2020131384 2020-09-23
RU2020131384A RU2020131384A (ru) 2020-05-28 2020-09-23 Лечение рака
GB2018062.6 2020-11-17
GBGB2018062.6A GB202018062D0 (en) 2020-11-17 2020-11-17 Treatment of cancer
PCT/EP2021/057588 WO2021239292A1 (en) 2020-05-28 2021-03-24 Treatment of cancer

Publications (1)

Publication Number Publication Date
AU2021280214A1 true AU2021280214A1 (en) 2023-02-02

Family

ID=75362569

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021280214A Pending AU2021280214A1 (en) 2020-05-28 2021-03-24 Treatment of cancer

Country Status (11)

Country Link
US (1) US20230210946A1 (https=)
EP (1) EP4157313A1 (https=)
JP (1) JP2023527209A (https=)
KR (1) KR20230028321A (https=)
CN (1) CN116133674A (https=)
AU (1) AU2021280214A1 (https=)
BR (1) BR112022024179A2 (https=)
CA (1) CA3184309A1 (https=)
IL (1) IL298507A (https=)
MX (1) MX2022014909A (https=)
WO (1) WO2021239292A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4475955A1 (en) * 2022-02-11 2024-12-18 Immutep S.A.S. Treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
GB201322626D0 (en) * 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
GB201500374D0 (en) * 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
JP2021534177A (ja) * 2018-08-16 2021-12-09 ジー１ セラピューティクス， インコーポレイテッド 医学的障害を治療するためのベンゾチオフェンエストロゲン受容体モジュレーター
WO2020047329A1 (en) * 2018-08-29 2020-03-05 Shattuck Labs, Inc. Chimeric proteins comprising extracellular domains and uses thereof

Also Published As

Publication number Publication date
KR20230028321A (ko) 2023-02-28
JP2023527209A (ja) 2023-06-27
US20230210946A1 (en) 2023-07-06
IL298507A (en) 2023-01-01
EP4157313A1 (en) 2023-04-05
CA3184309A1 (en) 2021-12-02
CN116133674A (zh) 2023-05-16
MX2022014909A (es) 2023-03-06
BR112022024179A2 (pt) 2023-02-07
WO2021239292A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
He et al. MRTX-500 phase 2 trial: sitravatinib with nivolumab in patients with nonsquamous NSCLC progressing on or after checkpoint inhibitor therapy or chemotherapy
EP3089749B1 (en) Combined preparations for the treatment of cancer
WO2024163641A2 (en) Formulations for treating cancer
AU2021280214A1 (en) Treatment of cancer
JP2025507017A (ja) 胃がんにおける抗ヒトｃｄ３９抗体、抗ヒトｐｄ－１抗体、及び化学療法による併用
US20240277804A1 (en) Triple combination therapy
Jeanson et al. MEDI 4736 (durvalumab) in non-small cell lung cancer
US20250368714A1 (en) Treatment of cancer
Li et al. Immunosuppressive tumor microenvironment shape pancreatic cancer unresponsive to current immunotherapies
CN118804760A (zh) 癌症的治疗
Zhou et al. Efficacies and adverse reactions of modified vitamin supplement programs before pemetrexed chemotherapy as a second-line treatment against epidermal growth factor receptor (EGFR) mutant wild-type lung adenocarcinoma
HK40114893A (en) Combined preparations for the treatment of cancer
Lisberg et al. P15. 08 Phase I Trial of in situ Vaccination With Autologous CCL21-Modified Dendritic Cells (CCL21-DC) Combined With Pembrolizumab for Advanced NSCLC
HK40011073B (en) Combined preparations for the treatment of cancer
Karampeazis et al. A dose escalation study of biweekly oral vinorelbine and gemcitabine in patients with solid tumors
HK1230495A1 (en) Combined preparations for the treatment of cancer
HK1230495B (en) Combined preparations for the treatment of cancer